Psychiatric Treatment Considerations With Direct Acting Antivirals in Hepatitis C

Sanjeev Sockalingam; Alice Tseng; Pierre Giguere; David Wong

Disclosures

BMC Gastroenterol. 2013;13(86) 

In This Article

Methods

We performed a Pubmed search using MeSH headings "hepatitis C" AND "boceprevir" OR "telaprevir" combined with "mental disorders", "psychotropic drugs" and "drug interactions". We limited our search to English language studies published between 2000-April 2013. References for all review articles were searched for additional studies as well as conference abstracts. Additional information on psychiatric adverse effects and DDIs with DAAs were requested from Vertex and Merck. Due to the limited literature, data on psychiatric adverse effects was also obtained from registration trials for boceprevir and telaprevir. Theoretical drug interactions were included in the respective sections. Due to available data on antidepressant efficacy in depressed HCV populations, we discussed potential DAA and antidepressant DDIs in the context of clinical evidence for specific antidepressant agents for treating depression during HCV therapy. Level of evidence was derived from 2 recent guidelines and existing reviews[26–29] and a previously published grading system[30] was used classify evidence for only studies examining antidepressant treatment of depression during HCV therapy.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....